Zydus Lifesciences Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Zydus Lifesciences hat ein durchschnittliches jährliches Gewinnwachstum von 15.5% verzeichnet, während die Branche Pharmaceuticals ein Gewinnwachstum gewachsen unter 16% jährlich einen Rückgang. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 7% pro Jahr. Zydus Lifesciences's return on equity is 17.9%, und die Nettomargen betragen 19.6%.

Wichtige Informationen

19.0%

Wachstumsrate der Gewinne

19.3%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	17.5%
Wachstumsrate der Einnahmen	7.5%
Eigenkapitalrendite	19.4%
Netto-Marge	20.2%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

Aufschlüsselung der Einnahmen und Ausgaben

Wie Zydus Lifesciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NSEI:ZYDUSLIFE Einnahmen, Ausgaben und Erträge (INR Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Jun 24	206,153	41,685	43,988
31 Mar 24	195,474	38,365	42,457
31 Dec 23	190,241	29,562	40,238
30 Sep 23	187,760	28,109	38,955
30 Jun 23	184,127	25,262	38,143
31 Mar 23	172,374	19,649	37,649
31 Dec 22	164,335	20,785	34,572
30 Sep 22	157,110	19,629	33,594
30 Jun 22	153,361	21,710	33,072
31 Mar 22	151,099	22,416	32,498
31 Dec 21	157,609	23,267	33,869
30 Sep 21	157,389	23,269	34,155
30 Jun 21	156,130	22,600	33,716
31 Mar 21	144,035	22,016	31,250
31 Dec 20	150,076	18,465	33,882
30 Sep 20	148,501	16,932	33,738
30 Jun 20	143,967	13,270	33,550
31 Mar 20	142,531	11,766	33,080
31 Dec 19	142,338	12,448	30,652
30 Sep 19	141,736	13,816	29,702
30 Jun 19	137,682	16,919	28,947
31 Mar 19	131,656	18,488	28,315
31 Dec 18	126,706	19,954	26,962
30 Sep 18	123,526	20,305	26,377
30 Jun 18	126,133	21,168	25,801
31 Mar 18	119,049	17,946	24,874
31 Dec 17	111,691	15,705	23,076
30 Sep 17	102,206	13,511	22,178
30 Jun 17	93,397	12,277	15,718
31 Mar 17	93,765	14,904	20,774
31 Dec 16	97,494	11,323	22,840
30 Sep 16	97,971	12,812	22,110
30 Jun 16	97,221	14,186	13,863
31 Mar 16	94,268	19,339	19,875
31 Dec 15	95,901	14,843	26,749
30 Sep 15	92,453	13,766	26,744
30 Jun 15	89,795	12,638	26,277
31 Mar 15	86,513	11,506	19,060
31 Dec 14	82,955	10,394	24,740
30 Sep 14	79,777	9,435	24,184
30 Jun 14	76,165	8,488	24,041
31 Mar 14	72,034	8,036	23,771
31 Dec 13	68,204	8,266	21,595
30 Sep 13	65,528	7,430	21,306

Qualität der Erträge: ZYDUSLIFE hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: ZYDUSLIFEDie aktuellen Gewinnspannen (19.6%) sind höher als im letzten Jahr (11.4%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ZYDUSLIFEIn den letzten 5 Jahren sind die Gewinne von 15.5% jährlich gestiegen.

Beschleunigtes Wachstum: ZYDUSLIFEDas Gewinnwachstum des Unternehmens im letzten Jahr (95.3%) übertrifft seinen 5-Jahres-Durchschnitt (15.5% pro Jahr).

Erträge im Vergleich zur Industrie: ZYDUSLIFE Das Gewinnwachstum im vergangenen Jahr (95.3%) übertraf das der Branche Pharmaceuticals 22.5%.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ZYDUSLIFEDie Eigenkapitalrendite des Unternehmens (17.9%) wird als niedrig angesehen.

Zydus Lifesciences Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023